Literature DB >> 34155702

Novel pathogenic variants in the RECQL4 gene causing Rothmund-Thomson syndrome in three Chinese patients.

Yingzi Zhang1, Wen Qin2, Huijun Wang2, Zhimiao Lin2, Zhanli Tang3, Zhe Xu1,4.   

Abstract

Rothmund-Thomson syndrome (RTS) is a rare autosomal-recessive disorder characterized by poikiloderma, short stature, sparse hair, skeletal abnormalities, and cancer predisposition. Mutations in ANAPC1 or RECQL4 have been identified to underlie RTS. Either Sanger sequencing or next-generation sequencing (NGS) was performed for three Chinese RTS patients. Copy number variants were called by the eXome-Hidden Markov Model using read-depth data of NGS, and the putative heterozygous deletion was confirmed by PCR with multiple primers. The breakpoints were identified by Sanger sequencing. All patients presented with characteristic features of poikiloderma, short stature, and sparse hair, eyelashes, and eyebrows. In addition, patient 1 had intellectual disability and speech delay, and patient 2 developed osteosarcoma when she was 13 years old. Biallelic RECQL4 variants were identified in all three patients. Five of the six variants were novel, including c.119-1G>A, c.2886-1G>A, c.2290C>T (p.Gln764*), and c.3552dupG (p.Arg1185Glufs*42), and a gross deletion encompassing exons 6 to 10. Our study expands the genetic and clinical spectrums of RTS. Furthermore, we reported the first heterozygous gross deletion in RECQL4.
© 2021 Japanese Dermatological Association.

Entities:  

Keywords:  zzm321990RECQL4zzm321990; Rothmund-Thomson syndrome; genotype-phenotype correlation; novel variants; truncating mutation

Mesh:

Substances:

Year:  2021        PMID: 34155702     DOI: 10.1111/1346-8138.16015

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  1 in total

Review 1.  Molecular Mechanisms of the RECQ4 Pathogenic Mutations.

Authors:  Xiaohua Xu; Chou-Wei Chang; Min Li; Chao Liu; Yilun Liu
Journal:  Front Mol Biosci       Date:  2021-11-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.